Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, has been selected by BIO-Europe 2022 to present at the Start-up Spotlight session on October 25, 2022 in Leipzig, Germany.
RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, has been selected by BIO-Europe 2022 to present at the Start-up Spotlight session on October 25, 2022 in Leipzig, Germany.
The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live pitch competition gives a group of hand-selected startups the opportunity to pitch in front of the BIO-Europe audience. Selected companies will present a four-minute pitch and participate in a live feedback session with a jury of leading investors, pharma dealmakers, and biotech business key opinion leaders who will evaluate the pitches and select the winner onsite.
“We’re looking forward to sharing our findings with this very innovative group,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. Dr. Rupalla will present Ymmunobio’s company focus on enabling new cancer treatments by increasing immune cell communication.
BIO-Europe 2022 takes place October 24-26 and attracts a wide range of business leaders, such as: senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. The competition will begin in Multi-purpose Room 3 at 3:30 pm at the Leipzig Messe in Leipzig, Germany, October 25, 2022.
ABOUT YMMUNOBIO
Ymmunobio AG is a preclinical stage oncology biotech company developing a novel class of CEACAM antibodies to treat cancer. Ymmunobio’s wholly owned CEACAM antibodies directly target immune cell communication, thereby increasing the efficiency of the immune system to fight cancer. Learn more on Ymmunobio’s website and follow on LinkedIn.
Media Contact: Kellyann Zuzulo, Director, Communications, 215-287-7291, kellyann@em-press.media
Investor Relations: Dr. Katrin Rupalla, info@ymmuno.bio